FDA Noncompliance Letter Hits Washington Biotech for Not Submitting Trial Results

A biotech in Friday Harbor, Wash., has been warned by the FDA for failing to report the findings of a phase 2 trial of a combination product for relieving lower urinary tract symptoms caused by benign prostatic hyperplasia.
Source: Drug Industry Daily